Ouellette Andrew, O'Connell Kristen, Kaczorowski Catherine
The University of Maine, Orono, ME, 04469, USA.
The Jackson Laboratory, Bar Harbor, ME, 04609, USA.
bioRxiv. 2025 May 14:2025.05.13.653830. doi: 10.1101/2025.05.13.653830.
Developing effective therapeutics for Alzheimer's Disease (AD) requires a better understanding of the molecular drivers of the disease. Our previous work nominated as a modifier of age-related cognitive decline and risk for AD. We tested the hypothesis that overexpression of DLGAP2 in the hippocampus would protect against cognitive and synaptic deficits in a susceptible F1 5XFAD model.
was overexpressed in the hippocampus of F1 hybrid 5XFAD and nontransgenic littermates using a viral approach. Cognitive function, electrophysiological properties, and dendritic spine morphology were assessed at 6 and 14 months of age.
overexpression impaired synaptic plasticity and exacerbated AD-related memory deficits but had minimal effect on spine structure or intrinsic neuronal properties.
We highlight the complex role of in AD pathology. Targeted interventions involving postsynaptic proteins must consider potential adverse effects on synaptic integrity and cognitive performance, particularly in the context of AD.
开发针对阿尔茨海默病(AD)的有效治疗方法需要更好地理解该疾病的分子驱动因素。我们之前的研究将[具体内容缺失]确定为与年龄相关的认知衰退和AD风险的调节因子。我们检验了以下假设:在易患AD的F1 5XFAD模型中,海马体中DLGAP2的过表达可预防认知和突触缺陷。
采用病毒方法在F1杂交5XFAD小鼠和非转基因同窝小鼠的海马体中过表达[具体内容缺失]。在6个月和14个月大时评估认知功能、电生理特性和树突棘形态。
[具体内容缺失]的过表达损害了突触可塑性,加剧了与AD相关的记忆缺陷,但对棘突结构或神经元内在特性影响最小。
我们强调了[具体内容缺失]在AD病理学中的复杂作用。涉及突触后蛋白的靶向干预必须考虑对突触完整性和认知表现的潜在不利影响,尤其是在AD的背景下。